Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?

Name: Assuming the community cardiologist is able to obtain reimbursement for PCSK9 inhibitors, in what segment of your patient population do you think this therapy is most under-utilized? How do price reductions for these agents affect your approach?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY